Clélia C.
- Country
- France
- Department
- Digestive Oncology
Research Overview
- Phase 1b Study of NP137 with Atezolizumab-Bevacizumab in First-Line Treatment of Unresectable Hepatocellular Carcinoma
- Pumitamig plus Combination Therapy Versus Nivolumab plus Combination Therapy in Previously Untreated Advanced or Metastatic Gastric, GEJ, or Esophageal Adenocarcinoma
- Phase 2 Randomized Open‑Label Study of Denikitug Monotherapy vs Combination Therapy in HER2‑negative Unresectable Metastatic Gastric/GEJ/Esophageal Adenocarcinoma
Data & Insights
Has run more than one trial at 261 of 474 partner sites.
Specializations
Gastrointestinal Oncology
This investigator specializes in treating advanced gastrointestinal cancers, with particular emphasis on colorectal cancer and gastroesophageal malignancies. Their research encompasses both early-stage and metastatic disease management.
- Colorectal Cancer Treatment
- Gastric and Esophageal Cancer Therapy
- Pancreatic Adenocarcinoma Management
Precision Medicine
The investigator focuses on biomarker-driven treatment approaches, particularly in cases involving microsatellite instability (MSI) and mismatch repair deficiency (dMMR). They work extensively with targeted therapies and personalized treatment strategies.
- Molecular Profiling
- HER2-Targeted Therapies
- Biomarker Analysis
Immunotherapy Applications
The investigator specializes in immunotherapy treatments for gastrointestinal cancers, including research into novel immune checkpoint inhibitors and combination therapeutic approaches.
- Checkpoint Inhibitor Therapy
- Combination Immunotherapy
- Treatment Resistance Strategies
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.